ATE394474T1 - Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen - Google Patents

Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Info

Publication number
ATE394474T1
ATE394474T1 AT98921011T AT98921011T ATE394474T1 AT E394474 T1 ATE394474 T1 AT E394474T1 AT 98921011 T AT98921011 T AT 98921011T AT 98921011 T AT98921011 T AT 98921011T AT E394474 T1 ATE394474 T1 AT E394474T1
Authority
AT
Austria
Prior art keywords
antigen
cells
activated
pbls
loaded
Prior art date
Application number
AT98921011T
Other languages
German (de)
English (en)
Inventor
Babita Agrawal
Mark Krantz
Mark Reddish
B Longenecker
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Application granted granted Critical
Publication of ATE394474T1 publication Critical patent/ATE394474T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98921011T 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen ATE394474T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08

Publications (1)

Publication Number Publication Date
ATE394474T1 true ATE394474T1 (de) 2008-05-15

Family

ID=21940709

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05076809T ATE491465T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
AT98921011T ATE394474T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05076809T ATE491465T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen

Country Status (10)

Country Link
US (1) US6600012B1 (enExample)
EP (3) EP1634949B1 (enExample)
JP (1) JP4480800B2 (enExample)
AT (2) ATE491465T1 (enExample)
AU (1) AU727863B2 (enExample)
CA (1) CA2289742C (enExample)
DE (2) DE69839443D1 (enExample)
DK (1) DK1634949T3 (enExample)
ES (1) ES2357960T3 (enExample)
WO (1) WO1998050527A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2001018035A2 (en) 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
EP1377275B1 (en) * 2001-03-27 2006-10-25 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
EP1499347A2 (en) 2002-03-15 2005-01-26 Department of Veterans Affairs, Rehabilitation R&D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
CA2482477A1 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
WO2004033667A2 (en) * 2002-10-10 2004-04-22 Department Of Veterans Affairs Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
EP1697399B1 (en) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1812052A1 (en) * 2004-11-02 2007-08-01 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
TW201615208A (zh) * 2005-06-28 2016-05-01 安柯席爾伊恩股份有限公司 以黏液性糖蛋白（ｍｕｃ-１）疫苗治療病人之方法
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
EP2025762A3 (en) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex tracking assay
RU2377994C1 (ru) * 2008-05-21 2010-01-10 Леонид Валентинович Загребин Способ иммунореабилитации онкозаболеваний
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
US9597392B2 (en) 2010-05-10 2017-03-21 Ascend Biopharmaceuticals Pty Ltd. Use of high molecular weight mannan for inducing and/or enhancing an immune response
BR112013021779A2 (pt) 2011-02-24 2017-09-19 Oncothyreon Inc vacina de glicolipopeptídeo baseada em muc1 com adjuvante.
EP2800762B1 (en) 2012-01-03 2018-01-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
BR112015028252A2 (pt) 2013-05-14 2017-07-25 Merck Patent Gmbh método de tratamento de câncer de pulmão por vacinação com lipopeptídeo muc-1
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
IL303806B2 (en) 2016-12-22 2024-05-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69511410T2 (de) 1994-06-13 1999-12-16 Unilever N.V., Rotterdam Bleichaktivierung
CA2192655A1 (en) * 1994-06-14 1995-12-21 Edgar G. Engleman Methods for in vivo t cell activation by antigen-pulsed dendritic cells
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
AU6330896A (en) * 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
WO1998037095A2 (en) 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Also Published As

Publication number Publication date
US6600012B1 (en) 2003-07-29
CA2289742C (en) 2013-07-16
EP0986636A1 (en) 2000-03-22
JP4480800B2 (ja) 2010-06-16
EP2341072A3 (en) 2013-10-30
EP1634949A1 (en) 2006-03-15
DE69839443D1 (de) 2008-06-19
DK1634949T3 (da) 2011-03-28
AU727863B2 (en) 2001-01-04
ATE491465T1 (de) 2011-01-15
EP0986636B1 (en) 2008-05-07
JP2001525668A (ja) 2001-12-11
AU7371298A (en) 1998-11-27
CA2289742A1 (en) 1998-11-12
ES2357960T3 (es) 2011-05-04
EP2341072A2 (en) 2011-07-06
WO1998050527A1 (en) 1998-11-12
EP1634949B1 (en) 2010-12-15
DE69842060D1 (de) 2011-01-27

Similar Documents

Publication Publication Date Title
ATE394474T1 (de) Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
DE69735851D1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
DE60120683D1 (de) Verfahren zur herstellung von membranvesikeln
ATE506962T1 (de) Von survivin abgeleitete peptide und deren verwendung
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
IL219223B (en) Non-naturally occurring antigen-presenting cells (nnapc) derived from drosophila melanogaster cells for use in preparing a suspension of cd8+ cells and methods for their manufacture
GR880100198A (el) Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου.
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
EP1249490A3 (en) In vitro activation of cytotoxic T cells
TR200001842T2 (tr) Papilloma virüs kapsomer aşı formülasyonları- kullanım metotları.
DE69942100D1 (de) Künstliche antigen-spezifischen zellen und zugehörige verfahren
DE3650184D1 (de) Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
ES2167561T3 (es) Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
DE69734974D1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
Slovin et al. Immunological approaches for the treatment of prostate cancer
ATE226638T1 (de) Retroviraler vektor und dessen verwendung in gentherapie
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
DE69920216D1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
WO2000015767A3 (en) Antigen-presenting cells and their use in therapy
UA36811A (uk) Спосіб визначення антитоксичної здатності замінників шкіри

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties